X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (67) 67
index medicus (67) 67
female (64) 64
oncology (54) 54
middle aged (26) 26
ovarian cancer (24) 24
cancer (23) 23
ovarian neoplasms - genetics (23) 23
ovarian neoplasms - pathology (23) 23
aged (22) 22
obstetrics & gynecology (20) 20
carcinoma (19) 19
adult (17) 17
breast cancer (17) 17
breast neoplasms - drug therapy (17) 17
article (14) 14
genetic aspects (14) 14
prognosis (14) 14
treatment outcome (14) 14
analysis (13) 13
breast neoplasms - pathology (13) 13
cell line, tumor (13) 13
survival (13) 13
chemotherapy (12) 12
disease-free survival (12) 12
gene expression regulation, neoplastic (12) 12
neoplasm staging (12) 12
aged, 80 and over (11) 11
expression (11) 11
research (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
tumors (10) 10
animals (9) 9
gene expression (9) 9
genes (9) 9
hematology, oncology and palliative medicine (9) 9
mutation (9) 9
endometrial cancer (8) 8
gene-expression (8) 8
medicine & public health (8) 8
ovarian-cancer (8) 8
trastuzumab (8) 8
antineoplastic agents - pharmacology (7) 7
antineoplastic agents - therapeutic use (7) 7
care and treatment (7) 7
endocrine system diseases (7) 7
health aspects (7) 7
mice (7) 7
obstetrics and gynecology (7) 7
ovarian neoplasms - mortality (7) 7
paclitaxel (7) 7
therapy (7) 7
adjuvant chemotherapy (6) 6
antineoplastic combined chemotherapy protocols - pharmacology (6) 6
breast neoplasms - genetics (6) 6
breast neoplasms - therapy (6) 6
carcinoma, ovarian epithelial (6) 6
chemotherapy, adjuvant (6) 6
clinical trials (6) 6
dna methylation (6) 6
docetaxel (6) 6
dose-response relationship, drug (6) 6
doxorubicin (6) 6
drug therapy (6) 6
endometrial neoplasms - pathology (6) 6
epirubicin - administration & dosage (6) 6
follow-up studies (6) 6
gene expression profiling (6) 6
genetic predisposition to disease (6) 6
genetics & heredity (6) 6
kaplan-meier estimate (6) 6
neoadjuvant therapy (6) 6
neoplasm grading (6) 6
neoplasms, glandular and epithelial - genetics (6) 6
ovarian neoplasms - drug therapy (6) 6
survival rate (6) 6
trial (6) 6
women (6) 6
angiogenesis (5) 5
breast (5) 5
breast neoplasms - metabolism (5) 5
breast neoplasms - mortality (5) 5
breast-cancer (5) 5
cells (5) 5
cyclophosphamide (5) 5
cystadenocarcinoma, serous - pathology (5) 5
gene expression regulation, neoplastic - drug effects (5) 5
genetics (5) 5
growth (5) 5
in-vivo (5) 5
molecular subtypes (5) 5
preoperative chemotherapy (5) 5
proportional hazards models (5) 5
randomized-trial (5) 5
risk factors (5) 5
signal transduction - drug effects (5) 5
transcriptome (5) 5
up-regulation (5) 5
adjuvant treatment (4) 4
antibodies, monoclonal - pharmacology (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet Oncology, ISSN 1470-2045, 05/2019, Volume 20, Issue 5, pp. 612 - 614
Journal Article
EBioMedicine, ISSN 2352-3964, 05/2019, Volume 43, pp. 9 - 10
Journal Article
Current Opinion in Obstetrics and Gynecology, ISSN 1040-872X, 12/2018, p. 1
Journal Article
Current Opinion in Obstetrics and Gynecology, ISSN 1040-872X, 02/2015, Volume 27, Issue 1, pp. 45 - 47
Journal Article
Current opinion in obstetrics & gynecology, ISSN 1040-872X, 02/2019, Volume 31, Issue 1, pp. 1 - 3
Journal Article
Cancer Research, ISSN 0008-5472, 08/2015, Volume 75, Issue 15 Supplement, pp. 4853 - 4853
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | BRCA MUTATION | POLY(ADP-RIBOSE) POLYMERASE | RANDOMIZED PHASE-2 | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | PROSTATE-CANCER | INHIBITORS | DNA-REPAIR | NEGATIVE BREAST-CANCER | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer | Index Medicus
Journal Article
Drugs, ISSN 0012-6667, 09/2007, Volume 67, Issue 14, p. 2110
Journal Article
by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum | Index Medicus | Abridged Index Medicus
Journal Article
BioMed Research International, ISSN 2314-6133, 2014, Volume 2014, pp. 602340 - 602340
  Analysis of free circulating fetal DNA will change the diagnostic approach in prenatal medicine drastically. [...]in cancer research a "liquid biopsy"... 
MEDICINE, RESEARCH & EXPERIMENTAL | LOCI | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CARCINOMA | Biomarkers - metabolism | Neoplasms - metabolism | Gynecology | Humans | Female | Obstetrics | DNA - blood | Medical research | Womens health | Genomics | Genes | Biomarkers | Genomes | Deoxyribonucleic acid--DNA | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 15, pp. 1796 - 1804
Journal Article
BioMed Research International, ISSN 2314-6133, 2014, Volume 2014, pp. 1 - 2
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 25, pp. 3351 - 3357
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.